(Q34754134)

4 August 2017

Serum iron in catatonia and neuroleptic malignant syndrome (English)

1 reference

4 August 2017

Lee JW

1

1 reference

PubMed ID

9777183

4 August 2017

language of work or name

English

0 references

publication date

1 September 1998

1 reference

4 August 2017

Biological Psychiatry

1 reference

4 August 2017

44

1 reference

4 August 2017

499-507

1 reference

4 August 2017

6

1 reference

Catatonia. A prospective clinical study

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Synergism of combined lithium-neuroleptic therapy: a double-blind, placebo-controlled case study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Catatonia. I. Rating scale and standardized examination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Catatonia. II. Treatment with lorazepam and electroconvulsive therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

7 January 2021

Serum iron in catatonia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Psychogenic catatonia with elevated creatine kinase and autonomic hyperactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Lithium Carbonate, Haloperidol, and Irreversible Brain Damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Neuroleptic malignant syndrome and catatonia: one entity or two?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

The neuroleptic malignant syndrome and its differentiation from lethal catatonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Treatment of catatonia with low-dose lorazepam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

The neuroleptic malignant syndrome, so-called. A survey of the world literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Neuroleptic malignant syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Benzodiazepines and catatonia: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Catatonia. Retarded and excited types.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Lithium treatment of a patient with periodic catatonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

ECT in the treatment of the catatonic syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Serum iron and neuroleptic malignant syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

A prospective analysis of 24 episodes of neuroleptic malignant syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Lorazepam for psychogenic catatonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

The neuroleptic malignant syndrome: agent and host interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Malignant catatonia--a continuing reality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

New data on lithium and haloperidol incompatibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Benzodiazepines in the treatment of catatonic syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Serum iron levels in neuroleptic malignant syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Catatonia and the neuroleptic malignant syndrome--a single entity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

Low Serum Iron Levels and Neuroleptic Malignant Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900109-7

10.1016/S0006-3223(98)00109-7

7 January 2021

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

9777183